[Utility of bolus somatostatin administration in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a controlled, non-randomized study]

Plain-language guide to PMID 16584693 (2006): placebo-controlled clinical trial study of Somatostatin, pancreatitis (after the acute phase).

Key Facts

PMID: 16584693
Journal: Gastroenterologia y hepatologia
Year: 2006
Study type: Clinical Trial
Authors: Vila JJ et al. (6 authors)
DOI: 10.1157/13085969

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Somatostatin in the context of pancreatitis (after the acute phase), published as a clinical trial.

The aim of this study was to evaluate the role of somatostatin as prophylaxis of ERCP-induced acute pancreatitis.

Why It Was Studied

Somatostatin is one of the most extensively evaluated drugs in the prophylaxis of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP), but its utility remains controversial.

Who Took Part

PubMed indexes the participants as older adults, both men and women.

This group was compared with another group composed of consecutive patients who had undergone ERCP in the 8 previous months, without somatostatin administration (placebo group).

How the Study Was Run

The researchers set it up as a placebo-controlled study.

A placebo (an inactive look-alike) gave the Somatostatin group a baseline to be compared against.

Both groups contained the same number of patients.

The following variables were recorded; sex, age, contrast injection in the duct of Wirsung, endoscopist, therapeutic maneuvers, and the development of post-ERCP pancreatitis.

What Was Measured

Somatostatin is one of the most extensively evaluated drugs in the prophylaxis of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP), but its utility remains controversial.

PubMed files the paper under topics including Cholangiopancreatography, Endoscopic Retrograde, Hormones, Pancreatitis and Somatostatin.

What This Means in Plain Language

The paper is a placebo-controlled study of Somatostatin in people with pancreatitis (after the acute phase).

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2006 (Gastroenterologia y hepatologia), a journal based in Spain.

More context: the Somatostatin compound page, Pancreatitis (after the acute phase) research.

Our Notes on the Compound

Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.